⏳ Fetching live dividend data...
Home › Calculator › RXDX Dividend Calculator 2026
Prometheus Biosciences, Inc. · NASDAQ
Price: $199.92 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
RXDX is not a dividend-focused stock
RXDX pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Prometheus Biosciences, Inc. (RXDX) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
No. Prometheus Biosciences, Inc. (RXDX) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. RXDX has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RXDX position with:
Real after-tax yield depends on where you live and how you hold RXDX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
RXDX pays quarterly — 4 times per year. Ex-div: —.
How RXDX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RXDX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2023-06-16 | 40,000 | $22.48 | $899.2K | ||
| D-Return | 2023-06-16 | 20,500 | $29.02 | $594.9K | ||
| D-Return | 2023-06-16 | 2,071 | $200.00 | $414.2K | ||
| D-Return | 2023-06-16 | 20,500 | $29.02 | $594.9K | ||
| D-Return | 2023-06-16 | 2,071 | $200.00 | $414.2K | ||
| D-Return | 2023-06-16 | 40,000 | $22.48 | $899.2K | ||
| D-Return | 2023-06-16 | 34,085 | $110.20 | $3.76M | ||
| D-Return | 2023-06-16 | 40,000 | $0.50 | $20.0K | ||
| D-Return | 2023-06-16 | 70,371 | $36.32 | $2.56M | ||
| D-Return | 2023-06-16 | 240,000 | $6.70 | $1.61M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare RXDX with peers: RXDX vs BPMC · RXDX vs CERE · RXDX vs IMGN
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RXDX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Prometheus Biosciences, Inc. (RXDX) is currently trading at $199.92, trading near its 52-week high. It does not currently pay a regular dividend.
Prometheus Biosciences, Inc. (RXDX) is a healthcare stock trading at $199.92. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever